Navigating the Ethical Landscape of Psychedelic-Assisted Psychotherapy: Determining the Optimal Level of Support

The debate, featuring Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways, and Dr. Max Wolff, Head of Psychotherapy Training and Research at the MIND Foundation, revolves around the fundamental role of psychotherapy in psychedelic-assisted therapy (PAT). Dr. Goodwin, a psychiatrist, advocates for a shift in focus towards the medicalization of psychedelic treatment, particularly for substances like psilocybin and LSD administered at high doses. He challenges the conventional notion that the term “psychedelic-assisted therapy” accurately reflects the primary role of the substance over therapy, contending that the psychedelic itself is the primary catalyst for therapeutic effects. On the other side of the debate, Dr. Wolff asserts that psychedelic therapy is inherently a form of psychotherapy. Drawing from an upcoming paper titled “Treatment with Psychedelics in Psychotherapy: Beyond Reductionism,” he argues that the subjective psychedelic experience plays a pivotal role in mediating long-term therapeutic outcomes. The discussion also delves into the interpretation of “psychological support” and questions whether the qualifications and training required for therapists in psychedelic treatments align with traditional psychotherapeutic practices. This debate underscores the ongoing evolution of psychedelic therapy, prompting considerations about the integration of therapeutic modalities and the individualized nature of patient care.